Ibogaine for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Ibogaine for Health & Longevity

Created on 06/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A single dose appears to interrupt drug withdrawal and craving and ease depression, anxiety, and trauma symptoms, with large, rapid reported effects. The evidence remains weak and mostly uncontrolled, and some carries financial conflicts. Ibogaine can dangerously disturb the heart's rhythm, cause coordination problems and seizures, and is illegal in the US. (Full Review)

Protocol

Dose
Single oral dose
Ibogaine hydrochloride; ~10 mg/kg in pharmacokinetic research, clinic doses vary
Setting
Continuous cardiac monitoring
Cardiac and laboratory screening beforehand; monitored recovery for at least 24 hours
Timing
Morning dosing
Keeps the prolonged 24+ hour experience and highest-risk cardiac window within staffed hours
Time to effect
Withdrawal & craving
Within hours
Rapid suppression after a single dose
Mood & trauma symptoms
Within days
Reported in studies, evident within days
Symptom benefits
One month or longer
Mood and trauma benefits persisted to one month or beyond

Benefits

Contraindications
  • Cardiovascular disease
  • Long-QT syndrome or QTc prolongation (>450 ms men / 470 ms women)
  • Recent myocardial infarction (<90 days)
  • Uncontrolled electrolyte disturbances
  • Significant liver impairment (Child-Pugh Class C)
  • Seizure disorders
  • Pregnancy
  • Severe psychiatric instability
    •
Key Interactions
  • QTc-prolonging drugs (amiodarone, sotalol, haloperidol, azithromycin, methadone)
  • Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine)
  • Opioids (including long-acting methadone)
  • OTC QTc-prolonging or CYP2D6 agents (diphenhydramine, dextromethorphan)
  • Stimulant or rhythm/serotonin-affecting supplements
  • Other psychoactive substances (alcohol, stimulants, 5-MeO-DMT)
    •

Risk & Side Effects

  • High: Cardiac arrhythmia and QTc prolongation; fatal toxicity / death
    •
  • Medium: Acute cerebellar and motor impairment; acute neuropsychiatric and gastrointestinal effects; potential neurotoxicity
    •
  • Low: Seizures
    •
  • Speculative: Long-term psychiatric or cognitive effects
    •

Monitoring

Marker Target Why
QTc interval (ECG) < 440 ms (men), < 450 ms (women) Detects the heart-rhythm delay that drives ibogaine's fatal arrhythmia risk
Serum potassium 4.0–4.5 mmol/L Low potassium worsens QTc prolongation and arrhythmia risk
Serum magnesium High-normal (≥ 0.9 mmol/L) Magnesium stabilizes cardiac rhythm and protects against QTc prolongation
Liver enzymes (ALT/AST) ALT/AST < 25 U/L Ibogaine is metabolized hepatically; impairment raises exposure and toxicity
CYP2D6 genotype Normal (extensive) metabolizer Poor metabolizers clear ibogaine slowly, raising toxic exposure

Cadence: Baseline screening before treatment; continuous ECG and vital-sign monitoring during dosing and for at least 24 hours after, with electrolyte rechecks as needed; clinical and psychological follow-up at 1 week, 1 month, then periodically.

Qualitative Assessment

  • Resolution or marked reduction of opioid withdrawal symptoms within 24–48 hours
  • Reduced craving and self-reported drug use over weeks to months
  • Improvements in mood, anxiety, sleep, and overall daily functioning
  • Absence of cardiac symptoms (palpitations, fainting, chest discomfort) during and after treatment
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.